Biovica International Overview

  • Founded
  • 2009
Founded
  • Status
  • Public
  • Employees
  • 23
Employees
  • Stock Symbol
  • BIOVIC B
Stock Symbol
  • Share Price
  • $5.71
  • (As of Friday Closing)

Biovica International General Information

Description

Biovica International AB is a biotech company. It develops and commercializes blood-based diagnostic tests with biomarkers that improve monitoring and evaluation of modern cancer treatments. Through collaboration with world- leading cancer institutes and pharmaceutical companies, it promotes the trend in healthcare for personalized treatment, with a primary focus on patient survival and benefits to society. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.

Contact Information

Website
www.biovica.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Stock Exchange
STO
Primary Office
  • Dag Hammarskjölds väg 54B
  • Uppsala Science Park
  • 752 37 Uppsala
  • Sweden
+46 018-444 00 00

Biovica International Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Biovica International Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.71 $5.90 $3.23 - $8.03 $162M 28.4M 50.9K -$0.18

Biovica International Financials Summary

In Thousands,
USD
TTM 31-Jul-2021 FY 2021 30-Apr-2021 FY 2020 30-Apr-2020 FY 2019 30-Apr-2019
EV 177,203 119,255 31,994 17,740
Revenue 248 237 173 333
EBITDA (4,401) (3,878) (2,659) (2,070)
Net Income (5,070) (4,498) (3,144) (2,386)
Total Assets 20,796 23,018 9,167 6,399
Total Debt 232 289 351 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biovica International Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biovica International‘s full profile, request access.

Request a free trial

Biovica International Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Biovica International AB is a biotech company. It develops and commercializes blood-based diagnostic tests with biomarke
Biotechnology
Uppsala, Sweden
23 As of 2021
000.00
000000000 000.00

000000

dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur si
0000000000000
Cambridge, United Kingdom
000 As of 0000
0000
000000000 00 0000

00000000

ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
0000000000000
Billerica, MA
00 As of 0000
00000
000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biovica International Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Abzena Private Equity-Backed Cambridge, United Kingdom 000 0000 000000000 00 0000
000000000 00000000 Formerly VC-backed Billerica, MA 00 00000 000000&0 00000
00000000 000000000 Formerly VC-backed Seattle, WA 000 00000 00000000 00000
00000 00000000 Formerly VC-backed Madison, WI 0000 00.000 00000000 00.000
00000000 Formerly VC-backed San Diego, CA 0000 00000 000000&0
To view Biovica International’s complete competitors history, request access »

Biovica International Patents

Biovica International Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-5227034-B2 Methods and kits for the determination of thymidine kinase activity and uses thereof Active 25-Feb-2005 000000000
US-8765378-B2 Method and kit for determination of thymidine kinase activity and use thereof Active 25-Feb-2005 000000000 0
JP-2008531012-A Methods and kits for the determination of thymidine kinase activity and uses thereof Granted 25-Feb-2005 000000000 0
US-9376707-B2 Kit for determination of thymidine kinase activity and use thereof Active 25-Feb-2005 000000000 0
US-20140255949-A1 Kit for determination of thymidine kinase activity and use thereof Granted 25-Feb-2005 C12Q1/485 0

Biovica International Executive Team (4)

Name Title Board Seat Contact Info
Anders Rylander Chief Executive Officer, Managing Director & Board Member
Cecilia Driving Chief Financial Officer & Executive Vice President
Robert Dann Senior Vice President, Marketing & US Business
Lars Holmqvist Chairman
To view Biovica International’s complete executive team members history, request access »

Biovica International Board Members (12)

Name Representing Role Since
000000 00000000 Biovica International Chief Executive Officer, Managing Director & Board Member 000 0000
000000 0000 Self Board Member 000 0000
000000 000000 Self Board Member 000 0000
0000 0000000000 00.0 Self Director of the Board and Senior Oncology Advisor 000 0000
000000 0ö00000000 00.0 Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Biovica International Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biovica International Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Biovica International‘s full profile, request access.

Request a free trial